Evidence map›Paper›PMID 32743474›Full record

ArticleIJU case reports2020

A case of inguinal cellular angiofibroma.

Rei Kamitani, Kazuhiro Matsumoto, Shinnosuke Fujiwara, Hirotaka Akita, Shuji Mikami, Kaori Kameyama, Masahiro Jinzaki, Mototsugu Oya

Abstract readCase Reports
In one paragraph

Article in IJU case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Paratesticular cellular angiofibroma: a case report.Journal of medical case reports · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rei KamitaniDepartment of Urology Keio University School of Medicine Tokyo Japan.
Kazuhiro MatsumotoDepartment of Urology Keio University School of Medicine Tokyo Japan.ORCID https://orcid.org/0000-0001-9222-0999
Shinnosuke FujiwaraDepartment of Urology Keio University School of Medicine Tokyo Japan.
Hirotaka AkitaDepartment of Diagnostic Radiology Keio University School of Medicine Tokyo Japan.
Shuji MikamiDepartment of Diagnostic Pathology Keio University School of Medicine Tokyo Japan.
Kaori KameyamaDepartment of Diagnostic Pathology Keio University School of Medicine Tokyo Japan.
Masahiro JinzakiDepartment of Diagnostic Radiology Keio University School of Medicine Tokyo Japan.
Mototsugu OyaDepartment of Urology Keio University School of Medicine Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCellular angiofibroma is a benign mesenchymal tumor that is rare and has a good prognosis. However, preoperative distinction of cellular angiofibroma from malignant tumors is difficult. CASE PRESENTATION: A 77-year-old man complained of a left inguinal mass, which was a solid, painless, mobile tumor measuring approximately 40 mm and contacted with the left spermatic cord. Based on his age, the location and imaging findings, a preoperative diagnosis of myxoid liposarcoma was made. The patient underwent left high inguinal orchiectomy with complete resection of the tumor. Histologically and immunohistochemically, the tumor had no feature of malignancy. A postoperative diagnosis of cellular angiofibroma was made. The patient remains free of disease recurrence 12 months after surgery.

conclusionCellular angiofibroma is a benign but rare tumor, which is sometimes difficult to distinguish from malignant neoplasms. Further studies are needed to accurately preoperatively diagnose this tumor.

Indexed as

cellular angiofibromainguinal tumormyxoid liposarcomaorchiectomy

Identifiers

PMID32743474
PMCPMC7292165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.